The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Open accessAbstract
Abstract Background The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB. Methods Published systematic reviews, meta-analyses, and a new individual patient data meta-analysis from 12,030 patients, in 50 studies, across 25 countries with confirmed pulmonary rifampin-resistant TB were used for this guideline. Meta-analytic approaches included propensity score matching to reduce confounding. Each recommendation was discussed by an expert committee, screened for conflicts of interest, according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Results Twenty-one Population, Intervention, Comparator, and Outcomes questions were addressed, generating 25 GRADE-based recommendations. Certainty in the evidence was judged to be very low, because the data came from observational studies with significant loss to follow-up and imbalance in background regimens between comparator groups. Good practices in the management of MDR-TB are described. On the basis of the evidence review, a clinical strategy tool for building a treatment regimen for MDR-TB is also provided. Conclusions New recommendations are made for the choice and number of drugs in a regimen, the duration of intensive and continuation phases, and the role of injectable drugs for MDR-TB. On the basis of these recommendations, an effective all-oral regimen for MDR-TB can be assembled. Recommendations are also provided on the role of surgery in treatment of MDR-TB and for treatment of contacts exposed to MDR-TB and treatment of isoniazid-resistant TB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Self-citationBarlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw118 · Cited by 3,061
A new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“Bedaquiline is bactericidal to nonreplicating and actively replicating mycobacteria, through ATP synthase inhibition, and has bactericidal and sterilizing activity in the murine model of TB infection (73).”
BackgroundThe Values and Value of Patient-Centered Care
Epstein, R. M., & Street, R. L. (2011) · The Annals of Family Medicine · doi:10.1370/afm.1239 · Cited by 1,956
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
(2005) · PsycEXTRA Dataset · doi:10.1037/e545842006-001 · Cited by 1,274
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,170
Self-citationWHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
Self-citationLewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992 · cited 7×
“The WHO-recommended standardized shorter-course 9-to 11-month regimen for MDR-TB was estimated by the guidelines committee to have minimal desirable effects (on treatment success, mortality, culture conversions) and small to moderate undesirable effects (adverse events, the use of drugs for which there is documented o…”
InfluentialSelf-citationAn Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy
Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1666st · Cited by 912
Self-citationYee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-626oc · Cited by 840
Self-citationFox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Towards tuberculosis elimination: an action framework for low-incidence countries
Lönnroth, K., Migliori, G. B., Abubakar, I., D'Ambrosio, L., de Vries, G., Diel, R., Douglas, P., Falzon, D., Gaudreau, M.-A., Goletti, D., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00214014 · Cited by 778
Self-citationLewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw778 · Cited by 773
Self-citationPatient-centered care and adherence: definitions and applications to improve outcomes
Robinson, J. H., Callister, L. C., Berry, J. A., & Dearing, K. A. (2008) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2008.00360.x · Cited by 721
Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin
Goble, M., Iseman, M. D., Madsen, L. A., Waite, D., Ackerson, L., & Horsburgh, C. R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280802 · Cited by 698
Self-citationTiming of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Gengiah, T., Nair, G., Bamber, S., Singh, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905848 · Cited by 666
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationEarlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis
Blanc, F.-X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Madec, Y., Marcy, O., Chan, S., Prak, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013911 · Cited by 612
Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 582
Schünemann, H. J., Jaeschke, R., Cook, D. J., Bria, W. F., El-Solh, A. A., Ernst, A., Fahy, B. F., Gould, M. K., Horan, K. L., Krishnan, J. A., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-197st · Cited by 577
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Lee, M., Lee, J., Carroll, M. W., Choi, H., Min, S., Song, T., Via, L. E., Goldfeder, L. C., Kang, E., Jin, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201964 · Cited by 560
Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., Becerra, M. C., Benedetti, A., Burgos, M., Centis, R., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001300 · Cited by 535
Self-citationTiming of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., Luetkemeyer, A. F., Hogg, E., Rooney, J. F., Wu, X., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013607 · Cited by 532
Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., & Nahid, P. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002595 · Cited by 503 · cited 2×
“compared with health facility–based DOT or self-administered therapy (11, 39).”
MethodSelf-citationPrediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
The CRyPTIC Consortium and the 100, 0. G. P. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800474 · Cited by 500
Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis
Hugonnet, J.-E., Tremblay, L. W., Boshoff, H. I., Barry, C. E., & Blanchard, J. S. (2009) · Science · doi:10.1126/science.1167498 · Cited by 494
Integration of Antiretroviral Therapy with Tuberculosis Treatment
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A. L., Gengiah, T., Gengiah, S., Naidoo, A., Jithoo, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014181 · Cited by 487
(2000) · PubMed · Cited by 486
Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival
Kitahata, M. M., Koepsell, T. D., Deyo, R. A., Maxwell, C. L., Dodge, W. T., & Wagner, E. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341106 · Cited by 456
Aminoglycoside-Induced Ototoxicity
Selimoglu, E. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207779313731 · Cited by 446
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Alsultan, A., & Peloquin, C. A. (2014) · Drugs · doi:10.1007/s40265-014-0222-8 · Cited by 444
Self-citationWorld Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Falzon, D., Schünemann, H. J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., & Weyer, K. (2017) · European Respiratory Journal · doi:10.1183/13993003.02308-2016 · Cited by 420
Sotgiu, G., Centis, R., D'Ambrosio, L., Alffenaar, J.-W. C., Anger, H. A., Caminero, J. A., Castiglia, P., De Lorenzo, S., Ferrara, G., Koh, W.-J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00022912 · Cited by 416
Self-citationTiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Self-citationFalzon, D., Jaramillo, E., & Schünemann, H. J. (2011) · European Respiratory Journal · doi:10.1183/13993003/erj.38.suppl_55.393 · Cited by 393
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Nunn, A. J., Phillips, P. P. J., Meredith, S. K., Chiang, C.-Y., Conradie, F., Dalai, D., van Deun, A., Dat, P.-T., Lan, N., Master, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811867 · Cited by 390
Falzon, D., Gandhi, N., Migliori, G. B., Sotgiu, G., Cox, H. S., Holtz, T. H., Hollm-Delgado, M.-G., Keshavjee, S., DeRiemer, K., Centis, R., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00134712 · Cited by 388
Self-citationBurden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study
Dodd, P. J., Gardiner, E., Coghlan, R., & Seddon, J. A. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(14)70245-1 · Cited by 370
Imperial, M. Z., Nahid, P., Phillips, P. P. J., Davies, G. R., Fielding, K., Hanna, D., Hermann, D., Wallis, R. S., Johnson, J. L., Lienhardt, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0224-2 · Cited by 360
Self-citationTreatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis
Chan, E. D., Laurel, V., Strand, M. J., Chan, J. F., Huynh, M.-L. N., Goble, M., & Iseman, M. D. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200308-1159oc · Cited by 336
Miotto, P., Tessema, B., Tagliani, E., Chindelevitch, L., Starks, A. M., Emerson, C., Hanna, D., Kim, P. S., Liwski, R., Zignol, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01354-2017 · Cited by 327
Seifert, M., Catanzaro, D., Catanzaro, A., & Rodwell, T. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119628 · Cited by 326
Aung, K. J. M., Van Deun, A., Declercq, E., Sarker, M. R., Das, P. K., Hossain, M. A., & Rieder, H. L. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0100 · Cited by 318
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
Jenkins, H. E., Tolman, A. W., Yuen, C. M., Parr, J. B., Keshavjee, S., Pérez-Vélez, C. M., Pagano, M., Becerra, M. C., & Cohen, T. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60195-1 · Cited by 314
Torok, M. E., Yen, N. T. B., Chau, T. T. H., Mai, N. T. H., Phu, N. H., Mai, P. P., Dung, N. T., Chau, N. V. V., Bang, N. D., Tien, N. A., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir230 · Cited by 312
Vernon, A., Burman, W., Benator, D., Khan, A., & Bozeman, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11467-8 · Cited by 308
PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSIS
Lehmann, J. (1946) · The Lancet · doi:10.1016/s0140-6736(46)91185-3 · Cited by 295
ethA , inhA , and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates
Morlock, G. P., Metchock, B., Sikes, D., Crawford, J. T., & Cooksey, R. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3799-3805.2003 · Cited by 288
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2508001 · Cited by 273
Masur, H., Brooks, J. T., Benson, C. A., Holmes, K. K., Pau, A. K., & Kaplan, J. E. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu094 · Cited by 269
Linezolid in vitro: mechanism and antibacterial spectrum
Livermore, D. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg249 · Cited by 269
Dheda, K., Shean, K., Zumla, A., Badri, M., Streicher, E. M., Page-Shipp, L., Willcox, P., John, M.-A., Reubenson, G., Govindasamy, D., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60492-8 · Cited by 246
Pietersen, E., Ignatius, E., Streicher, E. M., Mastrapa, B., Padanilam, X., Pooran, A., Badri, M., Lesosky, M., van Helden, P., Sirgel, F. A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62675-6 · Cited by 246
Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis
Jenkins, H. E., Yuen, C. M., Rodriguez, C. A., Nathavitharana, R. R., McLaughlin, M. M., Donald, P., Marais, B. J., & Becerra, M. C. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30474-1 · Cited by 246
Global burden of drug-resistant tuberculosis in children: a mathematical modelling study
Dodd, P. J., Sismanidis, C., & Seddon, J. A. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30132-3 · Cited by 227
Piubello, A., Harouna, S. H., Souleymane, M. B., Boukary, I., Morou, S., Daouda, M., Hanki, Y., & Van Deun, A. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0075 · Cited by 226
Linezolid: a review of safety and tolerability
Vinh, D. C., & Rubinstein, E. (2009) · Journal of Infection · doi:10.1016/s0163-4453(09)60009-8 · Cited by 213
Almeida, D., Ioerger, T., Tyagi, S., Li, S.-Y., Mdluli, K., Andries, K., Grosset, J., Sacchettini, J., & Nuermberger, E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00753-16 · Cited by 209
Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention
Nguyen, T. V. A., Anthony, R. M., Bañuls, A.-L., Nguyen, T. V. A., Vu, D. H., & Alffenaar, J.-W. C. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix992 · Cited by 203
Zheng, J., Rubin, E. J., Bifani, P., Mathys, V., Lim, V., Au, M., Jang, J., Nam, J., Dick, T., Walker, J. R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.475798 · Cited by 198
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon
Kuaban, C., Noeske, J., Rieder, H. L., Aït-Khaled, N., Abena Foe, J. L., & Trébucq, A. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0535 · Cited by 197
Peloquin, C. A., Hadad, D. J., Molino, L. P. D., Palaci, M., Boom, W. H., Dietze, R., & Johnson, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01036-07 · Cited by 185
Self-citationMitochondrial Toxicity Associated with Linezolid
Soriano, A., Miró, O., & Mensa, J. (2005) · New England Journal of Medicine · doi:10.1056/nejm200511243532123 · Cited by 181
Lechartier, B., & Cole, S. T. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00395-15 · Cited by 179
Marks, S. M., Flood, J., Seaworth, B., Hirsch-Moverman, Y., Armstrong, L., Mase, S., Salcedo, K., Oh, P., Graviss, E. A., Colson, P. W., et al. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2005.131037 · Cited by 179
Self-citationGillies, M. B., Ranakusuma, A., Hoffmann, T., Thorning, S., McGuire, T., Glasziou, P., & Mar, C. D. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.140848 · Cited by 173
Bruning, J. B., Murillo, A. C., Chacón, O., Barletta, R. G., & Sacchettini, J. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00558-10 · Cited by 170
von Groote-Bidlingmaier, F., Patientia, R., Sanchez, E., Balanag, V., Ticona, E., Segura, P., Cadena, E., Yu, C., Cirule, A., Lizarbe, V., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30426-0 · Cited by 170
Ettehad, D., Schaaf, H. S., Seddon, J. A., Cooke, G. S., & Ford, N. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70033-6 · Cited by 168
Self-citationRifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
Nijland, H. M. J., Ruslami, R., Suroto, A. J., Burger, D. M., Alisjahbana, B., van Crevel, R., & Aarnoutse, R. E. (2007) · Clinical Infectious Diseases · doi:10.1086/521894 · Cited by 166
Tanoue, L. T. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70174-3 · Cited by 165
Pulmonary resection for multi–drug resistant tuberculosis
Pomerantz, B. J., Cleveland, J. C., Olson, H. K., & Pomerantz, M. (2001) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2001.112339 · Cited by 164
Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis
Cegielski, J. P., Dalton, T. L., Yagui, M., Wattanaamornkiet, W., Volchenkov, G. V., Via, L. E., der Walt, M. L. V., Tupasi, T. E., Smith, S. E., Odendaal, R., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu572 · Cited by 161
Self-citationGenetic Factors in Aminoglycoside Toxicity
Fischel‐Ghodsian, N. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.1.27 · Cited by 160
De Lorenzo, S., Alffenaar, J. W., Sotgiu, G., Centis, R., D'Ambrosio, L., Tiberi, S., Bolhuis, M. S., van Altena, R., Viggiani, P., Piana, A., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00124312 · Cited by 160
Self-citationBedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence
Pontali, E., Sotgiu, G., D’Ambrosio, L., Centis, R., & Migliori, G. B. (2016) · European Respiratory Journal · doi:10.1183/13993003.01891-2015 · Cited by 159
Self-citationThe Arabinosyltransferase EmbC Is Inhibited by Ethambutol in Mycobacterium tuberculosis
Goude, R., Amin, A. G., Chatterjee, D., & Parish, T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00162-09 · Cited by 157
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries
Trébucq, A., Schwoebel, V., Kashongwe, Z. M., Bakayoko, A. S., Kuaban, C., Noeske, J., Hassane-Harouna, S., Souleymane, B., Piubello, A., Ciza, F., et al. (2017) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.17.0498 · Cited by 156
Matteo Zignol, E., Cabibbe, A. M., Dean, A. S., Glaziou, P., Alikhanova, N., Ama, M. C. G., Andres, S., Barbova, A. I., Borbe-Reyes, A., Chin, D. P., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30073-2 · Cited by 156
Harausz, E., Garcia‐Prats, A. J., Law, S. J., Schaaf, H. S., Kredo, T., Seddon, J. A., Menzies, D., Turkova, A., Achar, J., Amanullah, F., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002591 · Cited by 152
Self-citationWhat is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?
Sharma, S. K., & Dheda, K. (2019) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_579_19 · Cited by 152
Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis
Dharmadhikari, A. S., Mphahlele, M., Venter, K., Stoltz, A. C., Mathebula, R., Masotla, T., der Walt, M. L. V., Pagano, M., Jensen, P. A., & Nardell, E. A. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0834 · Cited by 149
Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance
Matteo Zignol, E., Dean, A. S., Falzon, D., Gemert, W. V., Wright, A., Deun, A. V., Portaels, F., Laszlo, A., Espinal, M., Pablos-Méndez, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1512438 · Cited by 148
Ferlazzo, G., Mohr-Holland, E., Laxmeshwar, C., Hewison, C., Hughes, J. A., Jonckheere, S., Khachatryan, N., Avezedo, V. D., Egazaryan, L., Shroufi, A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30100-2 · Cited by 147
Activity of Amoxicillin/Clavulanate in Patients with Tuberculosis
Chambers, H. F. “., Kocagöz, T., Şipit, T., Turner, J., & Hopewell, P. C. (1998) · Clinical Infectious Diseases · doi:10.1086/513945 · Cited by 146
Tuberculosis elimination: theory and practice in Europe
D’Ambrosio, L., Dara, M., Tadolini, M., Centis, R., Sotgiu, G., van der Werf, M. J., Gaga, M., Cirillo, D. M., Spanevello, A., Raviglione, M. C., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00198813 · Cited by 146
Self-citationGarfein, R. S., Collins, K. M., Muñoz, F. F. S., Möser, K., Cerecer, P., Raab, F., Rios, P., Flick, A., Zúñiga, M. L., Cuevas-Mota, J., et al. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0923 · Cited by 136
Mase, S., Chorba, T. L., LoBue, P. A., & Castro, K. G. (2013) · Cited by 134
Self-citationMigliori, G. B., Nardell, E. A., Yedilbayev, A., D’Ambrosio, L., Centis, R., Tadolini, M., van den Boom, M., Ehsani, S., Sotgiu, G., & Dara, M. (2019) · European Respiratory Journal · doi:10.1183/13993003.00391-2019 · Cited by 134
Self-citationBastos, M. L., Hussain, H., Weyer, K., García‐García, L., Leimane, V., Leung, C. C., Narita, M., Peña, J. M., Ponce‐de‐León, A., Seung, K. J., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu619 · Cited by 131
Self-citationPapastavros, T., Dolovich, L. R., Holbrook, A. M., et al. (2002) · PubMed · Cited by 126
Enhancing management of tuberculosis treatment with video directly observed therapy in New York City
Chuck, C., Robinson, E. W., Macaraig, M., Alexander, M., & Burzynski, J. N. (2016) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.15.0738 · Cited by 124
Marks, S. M., Mase, S., & Morris, S. B. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix208 · Cited by 123
Self-citationOxazolidinones Inhibit Cellular Proliferation via Inhibition of Mitochondrial Protein Synthesis
Nagiec, E. E., Wu, L., Swaney, S. M., Chosay, J. G., Ross, D., Brieland, J. K., & Leach, K. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3896-3902.2005 · Cited by 120
The Role of Pyrazinamide in Tuberculosis Chemotherapy
Steele, M. A., & Prez, R. M. D. (1988) · CHEST Journal · doi:10.1378/chest.94.4.845 · Cited by 120
Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update
Njire, M. M., Tan, Y., Mugweru, J., Wang, C., Guo, J. T., Yew, W.-W., Tan, S., & Zhang, T. (2015) · Advances in Medical Sciences · doi:10.1016/j.advms.2015.09.007 · Cited by 120
An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis
Bastos, M. L., Lan, Z., & Menzies, D. (2017) · European Respiratory Journal · doi:10.1183/13993003.00803-2016 · Cited by 115
Self-citationTreatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012
Bamrah, S., Brostrom, R. J., Fred, D., Setik, L., Song, R., Kawamura, L. M., Heetderks, A., & Mase, S. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0028 · Cited by 113
Self-citationAmoxicillin-Clavulanic Acid for Treating Drug-Resistant Mycobacterium tuberculosis
Nadler, J. P., Berger, J., Nord, J. A., Cofsky, R., & Saxena, M. (1991) · CHEST Journal · doi:10.1378/chest.99.4.1025 · Cited by 112
Tiberi, S., Payen, M., Sotgiu, G., D’Ambrosio, L., Guizado, V. A. A., Alffenaar, J. C., Arbex, M. A., Caminero, J. A., Centis, R., Lorenzo, S. D., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.02146-2015 · Cited by 112
Self-citationSafety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications
Ramachandran, G., & Swaminathan, S. (2015) · Drug Safety · doi:10.1007/s40264-015-0267-y · Cited by 111
Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi, N. R., Andrews, J. R., Brust, J. C. M., Montreuil, R., Weissman, D., Heo, M., Moll, A. P., Friedland, G. H., & Shah, N. S. (2011) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.11.0153 · Cited by 111
Self-citationTreatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection
O’Donnell, M. R., Padayatchi, N., Kvasnovsky, C., Werner, L., Master, I., & Horsburgh, C. R. (2013) · Emerging infectious diseases · doi:10.3201/eid1903.120998 · Cited by 111
Self-citationKhan, F. A., Salim, M. S., du Cros, P., Casas, E. C., Khamraev, A., Sikhondze, W., Benedetti, A., Bastos, M. L., Lan, Z., Jaramillo, E., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00061-2017 · Cited by 110
Self-citationFregonese, F., Ahuja, S. D., Akkerman, O. W., Arakaki-Sánchez, D., Ayakaka, I., Baghaei, P., Bang, D., Bastos, M. L., Benedetti, A., Bonnet, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30078-x · Cited by 110
Self-citationSeddon, J. A., Hesseling, A. C., Finlayson, H., Fielding, K., Cox, H. S., Hughes, J. A., Godfrey‐Faussett, P., & Schaaf, H. S. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit655 · Cited by 109
Self-citationSvensson, E. M., Svensson, R. J., Brake, L. H. M. T., Boeree, M. J., Heinrich, N., Konsten, S., Churchyard, G., Dawson, R., Diacon, A. H., Kibiki, G. S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy026 · Cited by 109
Meropenem-Clavulanic Acid Shows Activity against Mycobacterium tuberculosis In Vivo
England, K., Boshoff, H. I., Arora, K., Weiner, D., Dayao, E. K., Schimel, D. M., Via, L. E., & Barry, C. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05690-11 · Cited by 107
Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin
WEINER, M. H., Burman, W. J., Luo, C.-C., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01621-06 · Cited by 106
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
Pranger, A. D., van der Werf, T. S., Kosterink, J. G. W., & Alffenaar, J. C. (2019) · Drugs · doi:10.1007/s40265-018-1043-y · Cited by 103
Digital health for the End TB Strategy: developing priority products and making them work
Falzon, D., Timimi, H., Kurosinski, P., Migliori, G. B., Gemert, W. V., Denkinger, C. M., Isaacs, C., Story, A., Garfein, R. S., Bastos, L. G. D. V., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00424-2016 · Cited by 101
Self-citationHwang, T. J., Wares, D. F., Jafarov, A., Jakubowiak, W., Nunn, P., & Keshavjee, S. A. (2013) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0863 · Cited by 100
Cegielski, J. P., Kurbatova, E. V., der Walt, M. L. V., Brand, J., Ershova, J. V., Tupasi, T. E., Caoili, J., Dalton, T. L., Contreras, C. C., Yagui, M., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ910 · Cited by 99
Self-citationGarfein, R. S., Liu, L., Cuevas-Mota, J., Collins, K. M., Munoz, F. A., Catanzaro, D. G., Moser, K., Higashi, J. M., Al‐Samarrai, T., Kriner, P., et al. (2018) · Emerging infectious diseases · doi:10.3201/eid2410.180459 · Cited by 99
Horne, D. J. D. L., Pinto, L., Arentz, M., Lin, S.-Y. G., Desmond, E. P., Flores, L., Steingart, K. R., & Minion, J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.02724-12 · Cited by 95
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review
Sotgiu, G., D’Ambrosio, L., Centis, R., Tiberi, S., Esposito, S., Dore, S., Spanevello, A., & Migliori, G. B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030373 · Cited by 94
Self-citationBeekmann, S. E., Gilbert, D. N., & Polgreen, P. M. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.08.009 · Cited by 93
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
Tadolini, M., Lingtsang, R. D., Tiberi, S., Enwerem, M., D'Ambrosio, L., Sadutshang, T. D., Centis, R., & Migliori, G. B. (2016) · European Respiratory Journal · doi:10.1183/13993003.00637-2016 · Cited by 92
Self-citationDalcolmo, M. P., Gayoso, R., Sotgiu, G., D’Ambrosio, L., da Rocha, J. L., Borga, L., Montes, F. C. O. F., Braga, J. U., Galesi, V. M. N., Barreira, D., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02445-2016 · Cited by 92
Self-citationDeshpande, D., Alffenaar, J. C., Köser, C. U., Dheda, K. U. J., Chapagain, M. L., Simbar, N., Schön, T., Sturkenboom, M. G. G., McIlleron, H., Lee, P. S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy624 · Cited by 89
Hwang, T. J., Dotsenko, S., Jafarov, A., Weyer, K., Falzon, D., Lunte, K., Nunn, P. P., Jaramillo, E., Keshavjee, S. A., & Wares, D. F. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004143 · Cited by 87
ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update
Migliori, G. B., Sotgiu, G., Rosales-Klintz, S., Centis, R., D’Ambrosio, L., Abubakar, I., Bothamley, G. H., Caminero, J. A., Cirillo, D. M., Dara, M., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02678-2017 · Cited by 87
Self-citationTreatment of Multidrug‐Resistant Tuberculosis during Pregnancy: A Report of 7 Cases
Shin, S. S., Guerra, D., Rich, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374225 · Cited by 86
Savić, R. M., WEINER, M. H., Kenzie, W. R. M., Engle, M., Whitworth, W. C., Johnson, J., Nsubuga, P., Nahid, P., Nguyen, N. H., Peloquin, C. A., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.634 · Cited by 85
Self-citationA review of the use of ethionamide and prothionamide in childhood tuberculosis
Thee, S. A., Garcia‐Prats, A. J., Donald, P. R., Hesseling, A. C., & Schaaf, H. S. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.09.007 · Cited by 82
Self-citationFox, G. J., Mitnick, C. D., Benedetti, A., Chan, E. D., Becerra, M. C., Chiang, C., Keshavjee, S. A., Koh, W., Shiraishi, Y., Viiklepp, P., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw002 · Cited by 82
Self-citationKim, C. T., Kim, T.-O., Shin, H., Ko, Y. C., Choe, Y. H., Kim, H.-R., & Kwon, Y. S. (2018) · European Respiratory Journal · doi:10.1183/13993003.02467-2017 · Cited by 82
Intrinsic Macrolide Resistance in Mycobacterium smegmatis Is Conferred by a Novel erm Gene, erm (38)
Nash, K. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3053-3060.2003 · Cited by 80
Drug‐Resistant Tuberculosis and Pregnancy: Treatment Outcomes of 38 Cases in Lima, Peru
Palacios, E., Dallman, R., Muñoz, M., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598191 · Cited by 80
Tiberi, S., Sotgiu, G., D’Ambrosio, L., Centis, R., Arbex, M. A., Arrascue, E. A., Alffenaar, J. C., Caminero, J. A., Gaga, M., Gualano, G., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00214-2016 · Cited by 80
Self-citationMarrone, M. T., Venkataramanan, V., Goodman, M. G., Hill, A. C., Jereb, J., & Mase, S. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0198 · Cited by 78
Self-citationMonitoring Therapy Adherence of Tuberculosis Patients by using Video-Enabled Electronic Devices
Story, A., Garfein, R. S., Hayward, A. C., Rusovich, V., Dadu, A., Soltan, V., Oprunenco, A., Collins, K. M., Sarin, R., Quraishi, S., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2203.151620 · Cited by 77
Self-citationRisk factors for infectiousness of patients with tuberculosis: a systematic review and meta-analysis
Melsew, Y. A., Doan, T. N., Gambhir, M., Cheng, A. C., McBryde, E. S., & Trauer, J. M. (2018) · Epidemiology and Infection · doi:10.1017/s0950268817003041 · Cited by 77
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
Lange, C. G., Duarte, R., Jachym, M. F., Guenther, G., Guglielmetti, L., Olaru, I. D., Oliveira, O., Rumetshofer, R., Véziris, N., & van Leth, F. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201606-1097le · Cited by 75
Self-citationVia, L. E., England, K., Weiner, D. M., Schimel, D. M., Zimmerman, M. D., Dayao, E. K., Chen, R. Y., Dodd, L. E., Richardson, M., Robbins, K. K., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00115-15 · Cited by 71
Gonzalo, X., & Drobniewski, F. A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks395 · Cited by 71
Kranzer, K., Elamin, W. F., Cox, H. S., Seddon, J. A., Ford, N. P., & Drobniewski, F. A. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207245 · Cited by 71
Pharmacokinetics of Gyrase Inhibitors, Part 1: Basic Chemistry and Gastrointestinal Disposition
Sörgel, F., & Kinzig, M. (1993) · The American Journal of Medicine · doi:10.1016/s0002-9343(20)31139-6 · Cited by 70
Pontali, E., D’Ambrosio, L., Centis, R., Sotgiu, G., & Migliori, G. B. (2017) · European Respiratory Journal · doi:10.1183/13993003.00146-2017 · Cited by 69
Self-citationSatti, H., McLaughlin, M., Hedt‐Gauthier, B., Atwood, S. S., Omotayo, D. B., Ntlamelle, L., & Seung, K. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046943 · Cited by 68
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Tiberi, S., D’Ambrosio, L., Lorenzo, S. D., Viggiani, P., Centis, R., Sotgiu, G., Alffenaar, J. W. C., & Migliori, G. B. (2015) · European Respiratory Journal · doi:10.1183/13993003.01278-2015 · Cited by 68
Self-citationvan Altena, R., Dijkstra, J. A., van der Meer, M. E., Howard, J. B., Kosterink, J. G. W., van Soolingen, D., van der Werf, T. S., & Alffenaar, J. C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01400-16 · Cited by 67
Donald, P. R. (2001) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540152029954 · Cited by 66
The Role of Therapeutic Drug Monitoring in Mycobacterial Infections
Peloquin, C. A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tnmi7-0029-2016 · Cited by 66
Self-citationGupta, A., Mathad, J. S., Abdel‐Rahman, S. M., Albano, J. D., Botgros, R., Brown, V., Browning, R., Dawson, L., Dooley, K. E., Gnanashanmugam, D., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ991 · Cited by 63
Staib, A. H., Beermann, D., Harder, S., Fuhr, U., & Liermann, D. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90026-0 · Cited by 61
Arnold, A., Cooke, G., Kon, O. M., Dedicoat, M. J., Lipman, M. C. I., Loyse, A., Ster, I. C., & Harrison, T. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02586-16 · Cited by 59
Para-aminosalicylic acid: the return of an old friend
Donald, P. R., & Diacon, A. H. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00263-7 · Cited by 57
Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study
Vinnard, C., Winston, C. A., Wileyto, E. P., MacGregor, R. R., & Bisson, G. P. (2010) · BMJ · doi:10.1136/bmj.c4451 · Cited by 57
Long-term Mortality of Patients With Tuberculous Meningitis in New York City: A Cohort Study
Vinnard, C., King, L., Munsiff, S. S., Crossa, A., Iwata, K., Pasipanodya, J. G., Proops, D. C., & Ahuja, S. D. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw763 · Cited by 54
Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis
Lange, C. G., Alghamdi, W. A., Al‐Shaer, M. H., Brighenti, S., Diacon, A. H., DiNardo, A. R., Grobbel, H.-P., Gröschel, M. I., von Groote-Bidlingmaier, F., Hauptmann, M., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12780 · Cited by 54
Self-citationTho, D. Q., Török, M. E., Yen, N. T. B., Bang, N. D., Lan, N. T. N., Kiet, V. S., Châu, N. V. V., Dung, N. H., Day, J., Farrar, J., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00319-12 · Cited by 52
Denti, P., Garcia‐Prats, A. J., Draper, H. R., Wiesner, L., Winckler, J. L., Thee, S. A., Dooley, K. E., Savić, R. M., McIlleron, H., Schaaf, H. S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01521-17 · Cited by 51
Self-citationSinkou, H., Hurevich, H., Rusovich, V., Zhylevich, L., Falzon, D., de Colombani, P., Dadu, A., Dara, M., Story, A., & Skrahina, A. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.02049-2016 · Cited by 49
Ammerman, N. C., Swanson, R. V., Bautista, E. M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00636-18 · Cited by 48
Interventions to improve adherence to tuberculosis treatment: systematic review and meta-analysis
Müller, A. M., Osório, C. S., Silva, D. R., Sbruzzi, G., de Tarso, P., & Dalcin, P. D. T. R. (2018) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.17.0596 · Cited by 47
Zimmerman, M. D., Blanc, L., Chen, P., Dartois, V. A., & Prideaux, B. (2018) · Journal of Visualized Experiments · doi:10.3791/57402-v · Cited by 44
Esmail, A., Sabur, N. F., Okpechi, I. G., & Dheda, K. U. J. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.11 · Cited by 44
Prevention and modulation of aminoglycoside ototoxicity (Review)
Willems, P., Fasano, M., Magri, V., et al. (2008) · Molecular Medicine Reports · doi:10.3892/mmr.1.1.3 · Cited by 39
Clarithromycin is inactive against Mycobacterium tuberculosis
Truffot-Pernot, C., Lounis, N., Grosset, J. H. E., & Ji, B. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2827 · Cited by 39
Staß, H., Schühly, U., ller, J.-G. M., et al. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140001-00007 · Cited by 36
Ahmed, I., Jabeen, K., Inayat, R., & Hasan, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02020-12 · Cited by 35
Srivastava, S., Deshpande, D., Pasipanodya, J. G., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw483 · Cited by 35
Arentz, M., Pavlinac, P. B., Kimerling, M. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047370 · Cited by 33
Staß, H., & Kubitza, D. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140001-00005 · Cited by 32
Monitoring for Tuberculosis Drug Hepatotoxicity: Moving from Opinion to Evidence
Saukkonen, J. J., Powell, K. M., & Jereb, J. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201112-2174ed · Cited by 31
Silva, C. D. M., Hajihosseini, A., Myrick, J., Nole, J., Louie, A., Schmidt, S., & Drusano, G. L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00856-18 · Cited by 30
Pregnancy in patients with tuberculosis: a TBNET cross-sectional survey
Bothamley, G. H., Ehlers, C., Salonka, I., Skrahina, A. M., Orcau, À., Codecasa, L. R., Ferrarese, M., Pesut, D. P., Solovič, I., Dudnyk, A., et al. (2016) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-016-1096-4 · Cited by 28
Self-citationHypothyroidism due to ethionamide
McDonnell, M. E., Braverman, L. E., & Bernardo, J. (2005) · New England Journal of Medicine · doi:10.1056/nejm200506303522621 · Cited by 27
Managing multidrug-resistant tuberculosis in children
Schaaf, H. S., Garcia‐Prats, A. J., Hesseling, A. C., & Seddon, J. A. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000062 · Cited by 26
Self-citationKhan, M., Pillay, T., Moodley, J., Ramjee, A., & Padayatchi, N. (2007) · PubMed · Cited by 24
Evaluation of macrolides for possible use against multidrug-resistantMycobacterium tuberculosis
van der Paardt, A.-F., Wilffert, B., Akkerman, O. W., de Lange, W. C. M., van Soolingen, D., Sinha, B. N. M., van der Werf, T. S., Kosterink, J. G. W., & Alffenaar, J. C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00147014 · Cited by 23
Global TB Network: working together to eliminate tuberculosis
Silva, D. R., Rendón, A., Alffenaar, J. C., Chakaya, J. M., Sotgiu, G., Esposito, S., & Migliori, G. B. (2018) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562018000000279 · Cited by 23
Self-citationGroup 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis
Fox, G. J., Benedetti, A., Cox, H. S., Koh, W., Viiklepp, P., Ahuja, S. D., Pasvol, G., & Menzies, D. (2016) · European Respiratory Journal · doi:10.1183/13993003.00993-2016 · Cited by 22
Self-citationSchaaf, H. S., Garcia‐Prats, A. J., McKenna, L., & Seddon, J. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1421067 · Cited by 22
Self-citationEthionamide-induced hypothyroidism [Correspondence]
Dutta, B. S., Hassan, G., Waseem, Q., Saheer, S., & Singh, A. (2011) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.11.0388 · Cited by 19
Velásquez, G. E., Calderon, R. I., Mitnick, C. D., Becerra, M. C., Huang, C.-C., Zhang, Z., Contreras, C. C., Yataco, R. M., Galea, J. T., Lecca, L. W., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00632-16 · Cited by 14
Self-citationGama, E. M., Madan, J. J., Langley, I., Girma, M., Evans, D. H., Rosen, S. B., & Squire, S. B. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-014386 · Cited by 10
Bothamley, G. H., Lange, C. G., Albrecht, D., Anibarro, L., Gómez, N. A., Andersen, Å. B., Avsar, K., Bаlаsаnyants, G. S., Belton, M., Berastegui, C., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.09.007 · Cited by 8
Self-citationTsang, C. A., Shah, N., Armstrong, L., & Marks, S. M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz263 · Cited by 8
Self-citation
Cited by
Gopalaswamy, R., Shanmugam, S., Mondal, R., & Subbian, S. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00667-6 · Cited by 350
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
Mirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T. (2021) · European Respiratory Journal · doi:10.1183/13993003.03300-2020 · Cited by 301
Diagnosis and treatment of multidrug-resistant tuberculosis
Jang, J. G., & Chung, J. H. (2020) · Yeungnam University Journal of Medicine · doi:10.12701/yujm.2020.00626 · Cited by 140
Metadata
- Authors
- Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., Dalton, T. L., Duarte, R., Fregonese, F., Horsburgh, C. R., Ahmad Khan, F., Kheir, F., Lan, Z., Lardizabal, A., Lauzardo, M., Mangan, J. M., Marks, S. M., McKenna, L., Menzies, D., Mitnick, C. D., Nilsen, D. M., Parvez, F., Peloquin, C. A., Raftery, A., Schaaf, H. S., Shah, N. S., Starke, J. R., Wilson, J. W., Wortham, J. M., Chorba, T., & Seaworth, B.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-11-15
- Volume
- 200
- Issue
- 10
- Pages
- e93-e142
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2989551129
- Cited by
- 462
- References
- 188
- FWCI
- 38.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.